{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T19:51:49Z","timestamp":1716839509878},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T00:00:00Z","timestamp":1416441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00296-014-3180-2","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T12:36:35Z","timestamp":1416573395000},"page":"1021-1025","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis"],"prefix":"10.1007","volume":"35","author":[{"given":"Diana","family":"Hern\u00e1ndez-Fl\u00f3rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Valor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Mart\u00ednez-Estupi\u00f1\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"L\u00f3pez-Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indalecio","family":"Monteagudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza","family":"Naredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,20]]},"reference":[{"issue":"3","key":"3180_CR1","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1136\/ard.61.suppl_3.iii8","volume":"61","author":"J Sieper","year":"2002","unstructured":"Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(3):iii8\u2013iii18","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3180_CR2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G","volume":"41","author":"J Braun","year":"1998","unstructured":"Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41(1):58\u201367","journal-title":"Arthritis Rheum"},{"issue":"6 Suppl 28","key":"3180_CR3","first-page":"S67","volume":"20","author":"IE Horst-Bruinsma van der","year":"2002","unstructured":"van der Horst-Bruinsma IE, Clegg DO, Dijkmans BA (2002) Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs. Clin Exp Rheumatol 20(6 Suppl 28):S67\u2013S70","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"3180_CR4","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/ard.2007.072397","volume":"66","author":"MK Vries de","year":"2007","unstructured":"de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66(9):1252\u20131254","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3180_CR5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","volume":"65","author":"A Vultaggio","year":"2010","unstructured":"Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E (2010) Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 65(5):657\u2013661. doi: 10.1111\/j.1398-9995.2009.02280.x","journal-title":"Allergy"},{"key":"3180_CR6","first-page":"13","volume":"74","author":"I Nestorov","year":"2005","unstructured":"Nestorov I (2005) Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl 74:13\u201318","journal-title":"J Rheumatol Suppl"},{"issue":"12","key":"3180_CR7","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","volume":"72","author":"S Garces","year":"2013","unstructured":"Garces S, Demengeot J, Benito-Garcia E (2013) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72(12):1947\u20131955. doi: 10.1136\/annrheumdis-2012-202220","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3180_CR8","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552\u20131563","journal-title":"Arthritis Rheum"},{"issue":"4","key":"3180_CR9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.coi.2008.06.011","volume":"20","author":"L Aarden","year":"2008","unstructured":"Aarden L, Ruuls SR, Wolbink G (2008) Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 20(4):431\u2013435. doi: 10.1016\/j.coi.2008.06.011","journal-title":"Curr Opin Immunol"},{"issue":"1\u20132","key":"3180_CR10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jim.2011.07.019","volume":"372","author":"MH Hart","year":"2011","unstructured":"Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, Aarden LA, Rispens T (2011) Differential effect of drug interference in immunogenicity assays. J Immunol Methods 372(1\u20132):196\u2013203","journal-title":"J Immunol Methods"},{"issue":"6","key":"3180_CR11","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","volume":"46","author":"EW St Clair","year":"2002","unstructured":"St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(6):1451\u20131459","journal-title":"Arthritis Rheum"},{"issue":"10","key":"3180_CR12","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","volume":"4","author":"EA Maser","year":"2006","unstructured":"Maser EA, Villela R, Silverberg MS, Greenberg GR (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease. Clin Gastroenterol Hepatol 4(10):1248\u20131254","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"3180_CR13","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","volume":"46","author":"M Svenson","year":"2007","unstructured":"Svenson M, Geborek P, Saxne T, Bendtzen K (2007) Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 46(12):1828\u20131834. doi: 10.1093\/rheumatology\/kem261","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3180_CR14","doi-asserted-by":"crossref","first-page":"R178","DOI":"10.1186\/ar2867","volume":"11","author":"D Mulleman","year":"2009","unstructured":"Mulleman D, Meric JC, Paintaud G, Ducourau E, Magdelaine-Beuzelin C, Valat JP, Goupille P (2009) Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. Arthritis Res Ther 11(6):R178. doi: 10.1186\/ar2867","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3180_CR15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","volume":"59","author":"CH Seow","year":"2010","unstructured":"Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR (2010) Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 59(1):49\u201354","journal-title":"Gut"},{"issue":"4","key":"3180_CR16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden van der","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361\u2013368","journal-title":"Arthritis Rheum"},{"key":"3180_CR17","volume-title":"Statistics in Kinesiology","author":"W Vincent","year":"2012","unstructured":"Vincent W, Weir J (2012) Statistics in Kinesiology, 4th edn. Champaign, IL","edition":"4"},{"issue":"5","key":"3180_CR18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1037\/h0031619","volume":"76","author":"JL Fleiss","year":"1971","unstructured":"Fleiss JL (1971) Measuring nominal scale agreement among many raters. Psychol Bull 76(5):378","journal-title":"Psychol Bull"},{"issue":"4","key":"3180_CR19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1037\/h0026256","volume":"70","author":"J Cohen","year":"1968","unstructured":"Cohen J (1968) Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 70(4):213\u2013220","journal-title":"Psychol Bull"},{"issue":"12","key":"3180_CR20","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2011-200828","volume":"71","author":"C Plasencia","year":"2012","unstructured":"Plasencia C, Pascual-Salcedo D, Nuno L, Bonilla G, Villalba A, Peiteado D, Diez J, Nagore D, del Agua AR, Moral R, Martin-Mola E, Balsa A (2012) Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis 71(12):1955\u20131960. doi: 10.1136\/annrheumdis-2011-200828","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3180_CR21","first-page":"661","volume":"28","author":"S Arends","year":"2010","unstructured":"Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E, Houtman PM, Griep EN, Limburg PC, Kallenberg CG, Wolbink GJ, Brouwer E (2010) The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(5):661\u2013668","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"3180_CR22","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/apt.12733","volume":"39","author":"BG Levesque","year":"2014","unstructured":"Levesque BG, Greenberg GR, Zou G, Sandborn WJ, Singh S, Hauenstein S, Ohrmund L, Wong CJ, Stitt LW, Shackelton LM, King D, Lockton S, Ducharme J, Feagan BG (2014) A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn\u2019s disease. Aliment Pharmacol Ther 39(10):1126\u20131135","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"3180_CR23","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/FTD.0b013e31828d23c3","volume":"35","author":"C Steenholdt","year":"2013","unstructured":"Steenholdt C, Ainsworth MA, Tovey M, Klausen TW, Thomsen OO, Brynskov J, Bendtzen K (2013) Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn\u2019s disease. Ther Drug Monit 35(4):530\u2013538","journal-title":"Ther Drug Monit"},{"issue":"8","key":"3180_CR24","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/apt.12030","volume":"36","author":"N Vande Casteele","year":"2012","unstructured":"Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, van der Kleij D, Gils A, Dijkstra G (2012) Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 36(8):765\u2013771","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"3180_CR25","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1515\/cclm-2013-0461","volume":"51","author":"B Ruiz-Arguello","year":"2013","unstructured":"Ruiz-Arguello B, del Agua AR, Torres N, Monasterio A, Martinez A, Nagore D (2013) Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 51(12):e287\u2013e289","journal-title":"Clin Chem Lab Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-014-3180-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-014-3180-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-014-3180-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:28:28Z","timestamp":1559042908000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-014-3180-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,20]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["3180"],"URL":"https:\/\/doi.org\/10.1007\/s00296-014-3180-2","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,20]]}}}